Transfer Factors Study with Autistic Children

These children were given three capsules containing transfer factors, three times daily, for three months. Each patient was assessed prior to the treatment, six weeks into the study, and at the completion of the three-month study.... more

Transfer Factors and HIV

Included in this study were 25 HIV-infected patients (20 male and 5 female), ages 19 to 56 (15 patients ages 21-25). Individuals were classified according to V.I. Pokrovskys classification (1989) for HIV-infection... more

Transfer Factors and Inflammation

OBJECTIVE: To investigate i) whether the Dialyzable Leukocyte Extract (DLE) modulates the production of proinflammatory cytokines in leukocytes activated by the bacterial cell wall components lipopolysaccharide (LPS), lipoteichoic acid (LTA), and peptidoglycan (PGN); ii) the effect of DLE on LPS-stimulated endothelial cells;... more

Transfer Factors and Autoimmune Conditions


Multiple Sclerosis...

Diabetes Mellitus...

Atopic Dermatitis...

Chronic Fatigue Syndrome...

... more

Transfer Factors and Diabetes

Background Intensive lifestyle interventions can reduce the incidence of type 2 diabetes in people with impaired glucose tolerance, but how long these benefits extend beyond the period of active intervention, and whether such interventions reduce the risk of cardiovascular disease (CVD) and mortality, is unclear..... more



Benefits of Transfer Factors




Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-a) while decreasing DNA damage in patients with late-stage cancer. Pilot studies have suggested that a combination of Nutraceuticals can raise NK cell function and TNF-a alpha activity and result in improved clinical outcomes in patients with late stage cancer. The objective of the study is to determine if Nutraceuticals can significantly raise NK function and TNF levels in patients with late stage cancer. After informed consent was obtained, 20 patients with stage IV, end-stage cancer were evaluated (one bladder, five breast, two prostate, one neuroblastoma, two non-small cell lung, three colon, 1 mesothelioma, two lymphoma, one ovarian, one gastric, one osteosarcoma). enhanced transfer factors ( 3 tablets 3 times per day), IMUPlus® (non denatured milk whey protein, 40 gm/day); Intravenous (50 to 100 gm/day) and oral (1–2 gm/day) ascorbic acid; Agaricus Blazeii Murill teas (10 gm/day); Immune Modulator Mix (a combination of vitamin, minerals, antioxidants and immune-enhancing natural products); nitrogenated soy extract (high levels of genistein and dadzein) and Andrographis Paniculata (500 mg twice daily) were used. Baseline NK function by standard 4 h 51Cr release assay and TNF alpha and receptor levels were measured by ELISA from resting and phytohemagglutinin (PHA) stimulated adherent and non-adherent Peripheral Blood Mononuclear Cell (PBMC). Total mercaptans and glutathione in plasma were taken and compared to levels measured 6 months later. Complete blood counts and chemistry panels were routinely monitored. As of a mean of 6 months, 16/20 patients were still alive. The 16 survivors had significantly higher NK function than baseline (p<.01 for each) and TNF-a levels in all four cell populations studied (p<.01 for each). Total mercaptans (p<.01) and TNF-a receptor levels were significantly reduced (p<.01). It was also observed that hemoglobin, hematocrit and glutathione levels were significantly elevated. The only toxicity noted was occasional diarrhea and nausea. The quality of life improved for all survivors by SF-36 form evaluation. An aggressive combination of immunoactive Nutraceuticals was effective in significantly increasing NK function, other immune parameters and hemoglobin from PBMC or plasma in patients with late stage cancers. Nutraceutical combinations may be effective in late stage cancers. Clinical outcomes evaluations are ongoing.


Despite enormous expenditures, little real progress has been made in the treatment of most cancers. Cancer incidence in the United States has risen 60 percent since 1950 and 27 fold since 1900 according to Surveillance, Epidemiology, and End Results (SEER).[1] Each year one in two men and one in three women in the U.S. develop some form of cancer according to the American Cancer Society.[1] Mortality has climbed dramatically. In 1999, 560,000 people died of cancer in the U.S. alone. The mortality rate for cancer in 1994 was 6 percent higher than in 1970.[1] Major gains have been made using chemotherapy in childhood leukemias, testicular cancer and some rare cancers, but the ability of chemotherapy and radiation to alter mortality of most cancers is negligible at best. Because of these facts, many Americans are utilizing some sort of alternative medicine in their battle against cancer. Estimates range from 9% of patients by the National Cancer Institute (NCI) to 60% of patients by other estimates. It appears that only about 5% of patients completely abandon traditional treatments for alternatives.[2] There is a significant need for research to determine, which if any alternative therapies show promise in the treatment of cancers. The role of the immune system in fighting cancer was first proposed by Paul Ehrlich around 1900, and the concept renewed by Lewis Thomas in 1959 and MacFarlane Burnet in 1969. Various research centers have been looking at immunotherapy for some time, and in fact in certain cancers recombitant interleukin-2 (IL-2) and interferons are used, but these therapies are plagued with serious side-effects.[3] Various natural products have been shown to have immune modulating properties.

The importance of the immune system in cancer prevention and adjuvant therapy has been well-established. Penn reports the following evidences for the role of the immune system in the development of cancers.[4]


Children with immunodeficiency diseases have increased rates of lymphoma, leukemia and Hodgkin's disease.

High rates of Kaposi's sarcoma and lymphoma in HIV infected individuals.

In organ transplant patients on immunosuppressive medications, there is a 3 fold increase in malignancies including skin, lips, vulva, anus, liver, lymphoma and Kaposi's sarcoma.

Cancer risk increases with duration of immunosuppressive treatment. In a study of heart transplant patients, cancer incidence increased 3 fold after one year of immunosuppressive therapy and 26 fold after 5 y.

Patients with autoimmune diseases treated with immunosuppressive therapy showed increased incidence of acute leukemia, lymphoma, liver cancer, bladder cancer and skin cancer.

Secondary tumors are common in cancer patients who receive immunosuppressive chemotherapy treatment. These may include acute leukemias, lymphoma, and bladder cancers. However this increase may be due to the DNA damage caused by the chemotherapeutic agent.

The importance of Natural Killer (NK) cells in effective immunotherapy has been broadly accepted. Our laboratory has consistently found that stage 4 cancer patients typically have severely depressed NK function, and sometimes decreased numbers (unpublished data). This is consistent with a plethora of other research on the subject.[5] Decreases in NK function are believed to be, at least in part, attributable to neoplasm's ability to “steer” the immune system towards T-helper 2 (Th2) vs. cell mediated or T-helper 1 (Th1) immunity. Many cancers secrete interleukin-10 (IL-10) as part of this mechanism.


Page 1|2|3|4|5|6|7|8

Explanation of Transfer Factors

Have you ever wondered how many components of your body and immune system know what to do and when to do it? When a bacterium, virus or fungus enters your body, dozens of immune system cells, molecules and body chemicals move into action.... more

Transfer Factors Safety

From April 1974 to January 1999, using transfer factors produced in our laboratories, we treated a total of 1647 patients (pts) suffering from persistent viral infections.... more

Transfer Factors and Cytokines

Transfer factors are proteins that transfer the ability to express cell-mediated immunity from immune donors to non-immune recipients...... more

Dr. See's Study on Transfer Factors

Twenty patients, 12 men and 8 women, were selected for this in vivo study. The average age was 49.3. The twenty individuals were each level 3 or level 4 cancer patients..... more

Dr. See's Abstract and Peer Review on Transfer Factors

Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-a) while decreasing DNA damage in patients with late-stage cancer.... more

Russian Studies on Transfer Factors

Objective: To determine the extent to which enhanced transfer factors increases Natural Killer (NK) cell activity above baseline...... more

Transfer Factors and Premature Aging

The November 27, 2006 issue of the AMA journal Archives of Internal Medicine published the finding of researchers from Cornell University, Johns Hopkins, the University of Michigan, and the National Institute on Aging that older women with reduced levels of vitamin B6, vitamin B12 and selenium had a greater risk of developing disability in their activities of daily living over a three year follow-up period than those with higher levels. ... more